(Tromsø 13. December 2018) Biotec Pharmacon's (OSE: Biotec) subsidiary
ArcticZymes has signed a supply agreement with a major Japanese company for its
product Cod UNG.
ArcticZymes AS, a leader in the development and commercialization of enzymes
applied to molecular diagnostics, gene therapy, and protein purification,
announces a new dual track supply agreement for its specialized enzyme, Cod
UNG.
ArticZymes' Japanese customer intends to develop and manufacture molecular
biology assay products containing Cod UNG for the research market and molecular
diagnostic kits. In addition, the company has agreed to channel ArticZymes'
enzyme as a stand-alone product to its own existing customers, with specific
focus on the Chinese market where it has identified a need.
Biotec Pharmacon anticipates the deal to be worth approximately 1 million NOK of
revenue in 2019 with a potential recurring revenue stream of 1-3 million NOK
each subsequent year.
ArcticZymes Managing Director Jethro Holter said:
"The quality of our customer and the dual structure of the deal is great
validation of our Cod UNG enzyme. By having two different channels through which
to sell it - via molecular biology assay kits and via direct sales - this is an
ideal position to be in."
Christian Jørgensen, CEO, added:
"Today's deal is a good demonstration of how our new commercialisation team is
operating, as reported in the Q3 results. This is a competitive market to
operate in, which is why we are proud of our portfolio of top quality,
specialized enzyme products which are in demand from our customers and their
customers. We look forward to further growing our pipeline of products and deals
in the near year."
For more information, please contact:
Biotec Pharmacon
CEO Christian JørgensenMD Tel: +47 47 79 24 57
ArcticZymes, Jethro Holter Tel: +47 46 85 91 45
contact@arcticzymes.com
Instinctif Partners
Melanie Toyne-Sewell / Tel: +44 207 457 2020
Christelle Kerouedan biotecpharmacon@instinctif.com
/Deborah Bell
About Biotec Pharmacon ASA
Biotec Pharmacon ASA is a biotechnology company developing, producing and
marketing novel recombinant enzymes and immune modulating beta-glucans. It is
the parent company of ArcticZymes AS and Biotec BetaGlucans AS.
For more information, please visit the website: www.biotec.no.
About ArticZymes
ArcticZymes develops, produces and markets enzymes of marine origin used in
molecular DNA technologies and diagnostics, representing growth markets where
rapid technological developments are creating a strong demand for new and
improved enzymes.
For more information, please visit: www.arcticzymes.com.